Hims & Hers (HIMS) is down -6.1%, or -$1.89 to $29.16.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
- Sell Rating for Hims & Hers Health Due to High Pricing and Limited Market Penetration of New Offerings
- Cautious Outlook on Hims & Hers Health Amid Expansion and Margin Concerns
- Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
- Sell Rating for Hims & Hers Health Amid Low Margin Concerns and Competitive Pricing